NASDAQ$MYGN

Myriad Genetics Inc · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

Myriad Genetics reported Q4 2025, revenue of $209.8M, a net loss of $7.9M.

For Q4 2025, Myriad Genetics reported revenue of $209.8M, a net loss of $7.9M. The earnings release highlights segment trends, liquidity, and management commentary on the period.

  • Revenue $209.8M.
  • Net loss $7.9M.
  • Myriad Genetics discusses capital allocation and near-term priorities.

Headline financials

Total Revenue

$210M

No prior period
EPS (adj)

$0.04

No prior period
Total Test Volumes

382.0K

Previous: 374.0K+2.1%
GAAP Gross Margin

70.0%

No prior period
Net Income

-$7.9M

No prior period
Operating Income

-$5.7M

No prior period
Gross Profit

$147M

No prior period

Revenue & EPS history

Myriad Genetics · Revenue · Quarterly

$210M

Q4 2025
Beat estimate in 10 of 14 quarters(71%)
ActualEstimate

Revenue by segment

Myriad Genetics · $156M total across 3 segments · Q3 2023

  • Hereditary Cancer
    $86.5M+22.7%
  • Prenatal
    $39.5M+78.7%
  • Tumor Profiling
    $30.2M-1.9%

Forward guidance

Management discusses operating priorities, capital allocation, and sector-specific risks in the quarterly filing.

Tailwinds

  • Headline results and segment commentary anchor the quarter narrative.
  • Balance sheet and liquidity support ongoing operations or returns.
  • Strategic initiatives cited in the release.

Headwinds

  • Macro, rates, or input costs may pressure margins.
  • One-time items can affect year-over-year comparability.
  • Execution risk on guidance or restructuring plans.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-2.7%

Avg return

Earnings day

-6.0%

Avg return

5 days after

-4.5%

Avg return

30 days after

45%

29 / 65 earnings

Positive

+20.4%

Q3 2017

Best reaction

-43.7%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-18.3%-16.3%-9.1%
Q4 2025+5.7%+5.3%+5.5%
Q3 2025-21.0%-23.0%-10.4%
Q1 2025-41.3%-41.5%-30.0%
Q4 2024-14.8%-22.1%-33.1%
Q3 2024-0.9%-8.0%-13.9%
Q2 2024+3.1%+8.2%+7.0%
Q1 2024+19.9%+27.5%+11.7%
Q4 2023-5.8%-3.3%-7.0%
Q3 2023+4.3%-3.3%+5.6%
Q2 2023-9.3%-19.9%-15.4%
Q1 2023-0.8%-13.8%+10.2%
Q4 2022+14.6%+24.5%+20.5%
Q3 2022-21.4%-20.3%-1.9%
Q2 2022+5.9%+1.0%-15.9%
Q1 2022-1.6%-9.1%-11.7%
Q4 2021+3.7%-1.3%+6.5%
Q3 2021-6.1%-1.5%-18.1%
Q2 2021+12.8%+11.6%+16.9%
Q1 2021+4.6%-6.5%-6.8%
Q4 2020-3.1%+8.6%+1.7%
Q3 2020-6.7%-4.1%+4.4%
Q2 2020-28.8%-33.2%-44.6%
Q1 2020-38.1%-30.1%-23.6%
Q4 2019-43.7%-44.0%-39.0%
Q3 2019-22.9%-19.9%-28.9%
Q2 2019+3.3%+6.1%+4.3%
Q1 2019-14.3%-19.5%-16.1%
Q4 2018+15.0%+16.0%+13.0%
Q3 2018+15.1%+20.3%+35.0%
Q2 2018-1.7%-4.2%-7.5%
Q1 2018-0.6%+4.1%+9.1%
Q4 2017+11.0%+10.1%+28.6%
Q3 2017+20.4%+19.8%+9.5%
Q2 2017+6.6%+3.2%+23.6%
Q1 2017-16.8%-16.4%-15.6%
Q4 2016-34.3%-28.2%-32.4%
Q3 2016-7.4%
Q2 2016-7.1%
Q1 2016+10.2%
Q4 2015+5.0%
Q3 2015-2.5%
Q2 2015-7.4%
Q1 2015-12.3%
Q4 2014-5.8%
Q3 2014-10.0%
Q2 2014+14.1%
Q1 2014-0.0%
Q4 2013-7.7%
Q3 2013+9.0%
Q2 2013-2.6%
Q1 2013+13.5%
Q4 2012-1.0%
Q3 2012+1.7%
Q2 2012+3.1%
Q1 2012-0.7%
Q4 2009+4.7%
Q4 2011+4.7%
Q3 2010+5.7%
Q3 2011+5.7%
Q2 2011-0.7%
Q2 2010-0.7%
Q1 2010+5.5%
Q1 2011+5.5%
Q4 2010+5.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro